New US FDA program to help determine if device trials will lead to market approval
This article was originally published in SRA
The US Food and Drug Administration is inviting feedback on its plans to create a new voluntary process that would allow device trial sponsors to determine whether their pivotal study design would support a marketing application if it is successfully executed and meets its stated endpoints without raising unforeseen safety concerns1,2.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.
Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’
Regulatory and scientific discussions undertaken by the European Medicines Agency’s human medicines evaluation committee are finding their way into a new internal repository.